Teva makes and sells generic drugs, branded specialty medicines, and biosimilars. Generics are the core business, with the US accounting for roughly half of total revenue — Teva fills a high single-digit share of all generic prescriptions there. Outside the US, it has meaningful generic drug operations in Europe, Japan, Russia, and Israel. Its branded side focuses on neurology and immunology treatments. Additional revenue comes from selling active pharmaceutical ingredients to other drugmakers, contract manufacturing, and Anda, a US distributor that supplies generic and specialty drugs to pharmacies and healthcare providers. Customers include pharmacies, hospitals, insurers, and wholesale distributors.
Employees32,842IPOFeb 23, 2011HQ124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
to
Financials (MXN)
Profitability
Metric
Current
Margins
Gross Margin
52.1%
Operating Margin
23.1%
EBITDA Margin
18.9%
Net Margin
9.0%
OCF Margin
9.9%
FCF Margin
6.8%
Returns on Capital
ROE
21.4%
ROA
3.9%
ROIC
11.8%
ROCE
8.3%
ROC (Greenblatt)
47.2%
3Y ROIIC
−41.6%
Consistency
Years Profitable / 10Y
3
Valuation
Metric
Current
Earnings Multiples
P/E (TTM)
26.29
Forward P/E
16.85
P/E ex-NRI
11.93
Shiller P/E (CAPE)
—
Cash Flow Multiples
P/FCF
34.85
P/OCF
23.83
P/Owner Earnings
265.32
FCF Yield
2.88%
Enterprise Value Multiples
EV / EBIT
23.70
EV / Forward EBIT
32.43
EV / EBITDA
16.46
EV / Forward EBITDA
20.22
EV / Revenue
3.10
EV / Forward Revenue
3.26
Asset / Sales
P/S
2.35
P/B
4.95
P/Tangible Book
—
Growth-Adjusted
PEG
—
Capital Returns
Metric
Current
Dividends
Dividend Yield (TTM)
0.00%
Forward Dividend Yield
0.00%
3Y Dividend Growth
0.0%
Payout Ratio
0.00
5Y Yield on Cost
0.00%
Buybacks & Dilution
3Y Buyback Ratio
−1.20%
Combined
Shareholder Yield
2.84%
Balance Sheet
Metric
Current
Leverage
Debt / Equity
2.06
Gross Debt / EBITDA
5.17
Cash / Debt
0.22
Equity / Assets
0.21
Coverage
Interest Coverage
4.42
Short-Term Liquidity
Current Ratio
1.01
Quick Ratio
0.78
Cash Ratio
0.28
Composite Scores
Piotroski F-Score
7
Altman Z-Score
0.93
Split History
Date
Split
No split history found.
Ex-date
Amount
Pay date
2017-11-27
$0.085
2017-12-12
2017-08-25
$0.085
2017-09-14
2017-06-01
$0.34
2017-06-22
2017-02-28
$0.34
2017-03-20
2016-12-01
$0.34
2016-12-20
2016-08-18
$0.34
2016-09-08
2016-05-20
$0.34
2016-06-07
2016-02-25
$0.34
2016-03-14
2015-11-13
$0.34
2015-12-03
2015-08-18
$0.34
2015-09-03
10 of 114
View allDate
Transcript
Type
2026-07-29
Q2 2026 Teva Pharmaceutical Industries Limited.. Earnings Call Transcript
Earnings Call
2026-07-07
Teva Pharmaceutical Industries Limited..To Discuss IL-15 Vitiligo Phase 1b 24 Week Efficacy Results Transcript
Corporate Presentation
2026-06-08
Teva Pharmaceutical Industries Limited.. at Goldman Sachs Healthcare Conference Transcript
Conference Presentations
2026-05-12
Teva Pharmaceutical Industries Ltd at Bank of America Global Healthcare Conference Transcript
Conference Presentations
2026-04-29
Q1 2026 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Earnings Call
2026-03-10
Teva Pharmaceutical Industries Ltd at Barclays Global Healthcare Conference Transcript
Conference Presentations
2026-01-28
Q4 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Earnings Call
2026-01-13
Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference Transcript
Conference Presentations
2025-12-04
Teva Pharmaceutical Industries Ltd at Citi Global Healthcare Conference Transcript
Conference Presentations
2025-11-05
Q3 2025 Teva Pharmaceutical Industries Ltd Earnings Call Transcript
Earnings Call
10 of 55
5-Step DuPont Analysis
ROE %
21.17%
×
×
Net Margin %
8.98%
×
×
Operating Margin %
23.10%
Operating Income
MX$73.91B
÷
Revenue
MX$319.99B
×
Tax Burden
1.1475
Net Income
MX$28.74B
÷
Pretax Income
MX$25.05B
×
Interest Burden
0.3389
Pretax Income
MX$25.05B
÷
Operating Income
MX$73.91B
×
Asset Turnover
0.43
÷
Revenue
MX$319.99B
÷
Average Total Assets
MX$742.31B
Begin Total Assets
MX$789.26B
End Total Assets
MX$695.36B
×
Equity Multiplier
5.47
÷
Avg Total Assets
MX$742.31B
÷
Avg Stockholders Equity
MX$135.78B
Begin Equity
MX$128.66B
End Equity
MX$142.89B